Single-dose mass drug administration of azithromycin (AZT) is underway to eliminate trachoma worldwide. Studies in Ethiopia showed a reduction in all-cause childhood deaths after administration. To examine the effect of single-dose AZ MDA on prevalent malaria infections in a large prospective cohort of children and parents in Dodoma Province, Tanzania, we quantified the temporal prevalence of malaria parasitemia by real-time PCR for 6 months after single-dose AZT. In the first month after treatment but not in subsequent months, \textit{Plasmodium falciparum} infections were reduced by 73\% (95\% CI 43\%–89\%) in treatment versus control villages and differences remained significant (p = 0.00497) in multivariate models with village-level random effects. Genetic sequencing of \textit{P. falciparum} ribosomal L4 protein showed no mutations associated with AZT resistance. AZT mass drug administration caused a transient, 1-month anti-malarial effect without selecting for \textit{P. falciparum} ribosomal L4 resistance mutations in a region with a 10-year history of treating trachoma with this drug.

Malaria can be treated or prevented with the broad-spectrum antimicrobial drugs tetracycline or azithromycin (AZT) (1). In vitro, AZT interferes with malarial parasite replication by targeting the unique apicoplast organelle of the parasite (1). AZT inhibits malarial parasite growth 10-fold every 48 hours, and the pharmacokinetics of AZT predict that it remains at concentrations high enough to limit parasite growth for >1 week (2). AZT might interfere with transmission by exoerythrocytic inhibition of parasite liver stages in humans and mice (3) and by interference with oocinete and sporozoite production in mosquitoes (4). Monotherapy with AZT is not typically used to treat malaria. However AZT is highly effective against \textit{Chlamydia trachomatis}, the causative agent of trachoma, which causes blindness (5,6). Persons with malaria who live in trachoma-endemic regions may undergo repeated AZT therapy as part of the World Health Organization–sponsored global trachoma eradication program (7,8).

Data regarding the effects of AZ mass drug administration (MDA) on malaria are limited. In a cluster randomized trial in The Gambia, AZ MDA given in 3 doses (20 mg/kg) 7 days apart reduced malaria rates by half when measured at 1 time point in children 5–14 years of age (9). More recently, a 49\% reduction in the odds of death (95\% CI 29\%–90\%) was reported for children 1–9 years of age in an AZ MDA treatment group compared with controls in Ethiopia (10,11). Porco et al. suggested that reductions in malaria prevalence associated with AZT MDA might have contributed to observed decreases in overall deaths (10).

For malaria treatment, a randomized clinical trial that compared AZT/artesunate with artesunate/lumefantrine in Muheza, Tanzania, reported that the odds of treatment failure were 5 times greater (95\% CI 3.3–11.4) in the group that received AZT/artesunate (12). The authors postulated that the AZT/artesunate showed treatment failure because MDA for trachoma in Tanzania could have led to localized \textit{Plasmodium} spp. resistance to AZT (12). \textit{Plasmodium} spp. drug resistance to AZT has not been documented in the field. However, in vitro selection for AZT resistance identified a G76V mutation among conserved active site amino acids at position 71–79 in \textit{P. falciparum} apicoplast-encoded...
ribosomal protein L4 (PfRpl4) (PFC10_API0043) (1). A Cochrane meta-analysis report stated that “azithromycin’s future for the treatment of malaria does not look promising” (13) and cited studies in which AZT, although well tolerated, was inferior to tetracycline for malaria prophylaxis (14–17).

In the current study, we evaluated malaria prevalence in a cohort of 2,053 children and adults in central Tanzania to examine the effect of single dose AZ MDA on prevalent malaria infections. We also searched for PfRpl4 mutations that might confer P. falciparum AZT resistance.

Methods

Study Site and Sampling

Study participants were from 8 rural agricultural villages in Dodoma Province, central Tanzania (18–20). The study period was January 12, 2009–July 21, 2009 and was coincidental with a period in which rainfall was <60% of the average amount (21,22). AZT was offered to all the residents of the treatment villages, including residents not part of the follow-up investigation. Four treatment villages were selected on the basis of trachoma prevalence >10% in children 1–9 years of age (trachoma prevalence 12%, 18%, 18%, and 14%), rather than by randomization (18,19), which was consistent with World Health Organization AZT MDA guidelines for trachoma control (4). Four control villages with lower trachoma rates (8%–10%) were chosen on the basis of geographic proximity.

A complete census was conducted in the villages. In each village, 130 families with children <5 years of age were randomly selected for follow-up prevalence blood sampling; 1 child and 1 adult were randomly selected from each family. Sample size estimations were based on presurvey estimates of a malaria prevalence of 10% in children <5 years of age in the Dodoma region (23). Follow-up fingerprick blood sampling was performed at baseline and at 1, 3, 4, and 6 months later. Children were divided into 3 subgroups that were sampled once at weeks 2 (group 1), 6 (group 2), and 8 (group 3). Contemporaneous to the monthly blood sampling, staff members from villages conducted an active surveillance program in which children were visited weekly and screened for axillary temperature and respiratory disease (18,19).

Blood samples were collected on ProteinSaver903 (GE Healthcare, Pittsburgh, PA, USA) for analysis by real-time PCR for all participants at each scheduled monthly visit (20). When a fever (temperature ≥37.5°C) in adults and children was observed or when a caregiver reported a history of fevers in children during the weekly surveillance, a rapid diagnostic test (RDT) (Paracheck-Pf; Orchid Biomedical Systems, Goa, India) and thick and thin blood films were prepared. RDTs were performed by trained study staff and interpreted in the field at the time of sampling. Two experienced microscopists at the Amani Laboratory in Muheza, Tanzania, read the slides blinded to the PCR or RDT results. Discordant results were read by a third microscopist. Persons with positive results by RDT and all febrile children <5 years of age were treated with artemether/lumefantrine according to national guidelines and removed from later analysis.

Information on bednet ownership was obtained through standardized participant interviews. Latitude, longitude, and altitude of home locations were measured by using the GPSMAP 76 unit (Garmin, Olathe, KS, USA).

Quantitative PCR

DNA extraction and real-time PCR are described elsewhere (20). Five 3-mm diameter punches, equivalent to 25 mL of whole blood, were removed from the filter papers. DNA was extracted by using a commercial 96-well kit (Promega, Fitchburg, WI, USA). The DNA was concentrated by glycogen acetate and acetate/ethanol precipitation and low-speed (3,000 × g) centrifugation for 30 min.

Multiplex real-time PCR was used to amplify the 18S P. falciparum ribosomal gene with a Cy5-labeled probe (20). Samples were processed in duplicate on manually loaded 384-well plates. A 40-cycle standard PCR protocol was used in a CFX 384 real-time PCR Detection System Thermocycler (BioRad, Hercules, CA, USA). Baseline relative fluorescence units (RFUs) were readjusted by using Bio-Rad CFX manager software. The real-time PCR system also detected Borrelia spp. reported by Reller et al. (24). The sensitivity and specificity of the real-time PCR versus that of RDT or microscopy were reported by Schachterle et al. (20). The real-time PCR detected 1–100 parasites/mL and showed the highest sensitivity in latent class analysis on febrile study patients. For the monthly surveys, microscopic analysis was not performed for the 8,711 samples for which real-time PCR was conducted. The RFU cutoff used was greater than that for >50 negative blood samples from control patients at Johns Hopkins University. The cutoff of 650 RFUs for the last cycle of the highest real-time PCR replicate had a specificity of 100% for samples from the control group at Johns Hopkins University and a specificity of 94% for samples from febrile patients in Tanzania; microscopy was used as a reference method (20).

Single-Nucleotide Polymorphism Analysis of PfRpl4 Gene for AZT Resistance

Blood samples from treatment and control villages that had higher parasite densities by real-time PCR and microscopy were subjected to PCR amplification and whole gene fragment cloning into the pCR2.1 plasmid. Amplification and cloning were followed by full PfRpl4 gene DNA sequencing of multiple bacterial clones for each patient and examination of mutations anywhere in this gene (1).
Statistical Analysis

Data were analyzed from the perspective of an intention to treat in which participants from AZT MDA–treated villages who refused treatment were classified with those who accepted AZT as members of treatment villages. Univariate ratios were used to compare prevalence proportions in treated versus untreated villages. CIs for ratios that compared proportions of prevalent infection in treated versus untreated villages were estimated by using 2-sided exact binomial tests.

Maps were used to display geospatial patterns in infection prevalence and malaria clustering over time (Google Maps, Mountain View, CA, USA, and Quantum Geographic Information System Open Source Geospatial Foundation Project [www.qgis.org/en/site/]). Geographic coordinates of P. falciparum–positive and –negative blood samples were projected into kilometers, and locations were smoothed by using quadratic kernel intensity estimation. Kernel intensity estimators predict spatial intensity at unsampled points from nearby sampled points by using a quadratic function to heavily weight the nearest measured points and de-emphasize points sampled at greater distances. Weighted integrals were used to estimate intensity smoothing parameters for quadratic functions, assuming a 2-dimensional (i.e., spatial), stationary, isotropic point pattern process. Spatial odds ratios (ratio of kernel intensities from positive blood samples to kernel intensities from negative blood samples) (25), were determined for P. falciparum.

To examine the effect of AZT MDA while adjusting for malaria clusters observed on maps, we used multivariate logistic models with random effects to compare odds of prevalent malaria infection for AZT MDA treatment villages with odds for control villages. Random intercepts were fit to account for the multilevel or hierarchical design that nested persons within villages. This model enabled accurate statistical inference by adjusting CIs and p values for P. falciparum clusters in villages, and this inference was apparent in prevalence maps (25). Residual spatial autocorrelation was eliminated by restricting models to 1 sampling interval (26). Multiple models that examined the effect of AZT MDA on prevalent malaria were fit to control for confounding by other drivers of malaria prevalence and to address the robustness of standard errors to potential spatial residual autocorrelation. Altitude and self-reported bednet ownership were held constant to control for confounding in the multivariate model. A priori, we believed any AZT MDA effect would be most perceptible between month 1 and baseline.

To distinguish between the effect of AZT on prevalence and incident infections, we performed a sensitivity analysis for only P. falciparum infections that had been preceded by a negative P. falciparum test result in the previous sampling interval. These data also underwent a second sensitivity analysis that included participants treated with artesunate/lumefantrine who had been removed from the previous analyses.

Data management and analysis were conducted by using R statistical software (27). R with the SPLANCS package was used for kernel intensity estimation (28), and the LME4 package was used for the random effects model (29). All R code is available upon request.

Results

Characteristics of Study Population

The study site in the Kongwa District of Tanzania included 8 villages and 12,898 persons. Four villages were chosen on the basis of increased prevalence of trachoma (>10%) in children 1–9 years of age. Excluded were 34 of 66 villages that had received AZT MDA in the previous year. In the 4 villages that received AZT MDA, 6,252 persons received AZT and 642 did not receive AZT. A census in untreated control villages identified 5,991 persons. These villages were chosen because of geographic proximity to treatment villages. In each village, pairs of a parent and a child <5 years of age were randomly chosen for inclusion (1,045 persons in the AZT MDA treatment group and 1,008 persons in the control group for follow-up) (Figure 1). Blood samples for real-time PCR testing were collected from participants at baseline and at months 1, 3, 4, and 6.
(4,437 patient-time samples from AZT MDA treatment villages and 4,274 patient-time samples from control villages). At any follow-up period after baseline, 1,010 (97%) study participants in AZT MDA villages who received AZT and 976 (97%) study controls were sampled for real-time PCR at least once. At baseline, treatment and control villages reported antimalarial drug use, latrine access, education (based on the highest level of education attained by the father), and home elevations. However, self-reported bednet ownership and fever histories were higher in treatment villages than in control villages (p<0.05) (Table 1).

Univariate Analysis by Time

Overall, the proportion of *P. falciparum*–infected participants was highest (6%) at baseline. Infections decreased sharply in treated villages and gradually in control villages throughout follow-up period (Figure 2). At the baseline evaluation, 6% (53/854) of participants from AZT MDA treatment villages were positive for *P. falciparum* compared with 6% (54/894) of participants from AZT MDA control villages. No differences in odds of infection were observed between control and treatment villages (odds ratio 1.03, 95% CI 0.68–1.55) (Figure 3, Table 2).

By month 1, *P. falciparum* prevalence in AZT MDA treatment villages decreased to 2% (14/851) and *P. falciparum* prevalence in AZT MDA control villages decreased to 5% (37/779). The odds ratio for AZ MDA treated villages compared with control villages was 0.34 (95% CI 0.17–0.64), which is consistent with a 66% reduction in the odds of *P. falciparum* infection in AZT MDA treatment participants compared with AZT MDA control participants. Beyond month 1, the association between of AZT MDA and reduced prevalence of malaria infection decreased. However, overall rates of *P. falciparum* infection decreased below levels for which reliable inferences could be made.

A village level comparison of changes in malaria prevalence for AZT MDA treatment villages versus prevalence in control villages indicated that 1 village in each group had no change in malaria prevalence, and 3 AZ MDA treatment villages had a significant (p<0.05, by Fisher exact test) decrease in malaria prevalence (p = 0.489, p = 0.0002, and p = 0.0005) and 2 in the control group had significant (p = 0.0008 and p = 0.001) increases. Village 5 in the control group had a significant (p = 0.0001) decrease (Figure 4; online Technical Appendix Table 1, wwwnc.cdc.gov/EID/article/20/6/13-1302-Techapp1.pdf).

In a subgroup of 200 children examined for malaria infection at weeks 2, 6, and 8, the malaria prevalence of 2%–5% was lower than the 10% expected (23) Thus, reliable prevalence comparisons were not relevant. During the study, febrile patients were tested by RDT and microscopy. During the critical period of 5–42 days after AZT MDA, 46 and 48 children in the treatment and control villages, respectively, were evaluated for fever. Among febrile children, only 5 children from treatment villages and 3 children from control villages were positive by real-time PCR.

Multivariate Analysis

At month 1, reductions in *P. falciparum* malaria prevalence were observed by logistic regression models that controlled for differences in self-reported bednet ownership and home altitude (Table 3) and included village level random effects. The odds of *P. falciparum* infection were 63% (95% CI 28%–81%) but less in treated villages than in control villages after adjusting for bednet ownership and home altitude in a model with village-level random intercepts. Because self-reported history of fever, malaria medication, latrine access, and education of the head of the household were not associated with malaria prevalence and did not appreciably alter the interpretations of the multivariate models, they were not included in the reported estimates. As was evident in univariate analysis, no differences in malaria rates existed at baseline, and the association between AZT MDA and reduced malaria rates decreased after the first month of follow up.

Spatial information on home locations enabled a thorough examination of residual spatial autocorrelation. A total of 51% (19/37) of *P. falciparum* infections at month 1 occurred in control village 8 (Figure 4), which raised concerns that residual spatial autocorrelation artificially decreased CIs from the reported models despite use of the random effects model. However, a variogram of standardized residuals from the model suggested that residual spatial autocorrelation was appropriately controlled by the village level random effects. The data were reanalyzed with incident infections that had been preceded by a negative real-time PCR result for *P. falciparum*; results did not change appreciably. We also observed an age-independent

### Table 1. Comparison between azithromycin MDA treatment and control participants at baseline, Tanzania, January 12–July 21, 2009*

| Variable                               | MDA treatment group | MDA control group |
|----------------------------------------|---------------------|-------------------|
| Bednet ownership, yes/no†              | 457/725 (63)        | 328/789 (42)      |
| History of fever, yes/no†              | 26/813 (3)          | 10/869 (1)        |
| Malaria medication, yes/no             | 157/814 (19)        | 161/869 (19)      |
| Latrine access, yes/no                 | 297/981 (30)        | 276/971 (28)      |
| Education of head of household, yes/no | 4.2 (3.41)          | 3.2 (3.46)        |
| Altitude, m                            | 1,206 (32.89)       | 1,200 (45.99)     |

*Values are no. positive/no. tested (%) for categorical measures or mean (SD) for continuous measures. MDA, mass drug administration. †p<0.05 by χ² test.
Short-Term Malaria Reduction by Azithromycin

decrease in malaria prevalence at month 1 for persons 1–10 years of age (univariate analysis) and for persons >10 years of age (univariate analysis and multivariate analysis) (on-line Technical Appendix Table 2).

Analysis of PfRpL4 Mutations Associated with Azithromycin Resistance

Sequencing of full-length *P. falciparum* ribosomal L4 protein was performed for samples from 12 patients. We did not find evidence of single-nucleotide polymorphisms (SNPs) conferring AZT resistance in amino acid region 71–79 (1). A synonymous SNP at position K36 was found in all bacterial plasmid clones from samples of 1 patient and in a *P. falciparum*–positive control patient who was not from Tanzania. A single plasmid clone from a sample of participant from an AZT MDA control village contained a nonsynonymous SNP in the active site of the PfRpL4 gene at A78S. However, 17 other plasmid clones from the same blood sample did not contain the mutation, which suggested the aberrant sequence resulted from a Taq
polymerase error during plasmid cloning of the PfRpL4 gene. Moreover, restriction enzyme HindIII, which was specific for the nonsynonymous SNP at A78S, did not digest multiple PCR amplicons from the original patient blood sample, which further suggested that the SNP on the PfRpL4 gene was present at a low concentration or may have been an artifact of the Taq polymerase amplification. A78S has not been identified in other mutant bacteria associated with AZT resistance (1). Eighteen other nonsynonymous mutations were found in samples from participants from AZT MDA treatment villages, but these mutations were not in conserved amino acid regions for PfRpL4 associated with AZT resistance in bacteria or the selected P. falciparum (except for an I39S were single occurrences among multiple clones from a single patient). Four synonymous SNPs were also detected (Table 4).

**Discussion**

AZT MDA was associated with a minimum reduction of 66% in odds of P. falciparum infection compared with odds of reduction for controls in the first month after drug administration, as shown by univariate and multivariate models on an individual level. Beyond 1 month, prevalence in treatment and control groups decreased, and there was no difference in prevalence between treatment and control groups. In addition, no mutations were detected in samples from treated persons who had parasitemias after drug treatment in the only gene associated with in vitro selection of AZT resistance. However, these results show more modest effects than those of other studies of AZT MDA, which reported large reductions in malaria (9) and that AZT MDA protection against malaria contributed to broader decreases in illness and death (10).

Because our data were analyzed from the perspective of an intention to treat, participants who did not receive AZT but lived in villages that received AZT MDA were classified with those who received AZT. The intention-to-treat analysis could have biased reported results toward the null because persons in AZT MDA treatment villages who benefited from AZT might have been more likely to become infected (online Technical Appendix Tables 3, 4). Because intention-to-treat analysis would probably bias results toward the null, we believe that it was a conservative analytic assumption.

An additional potential confounder is that all febrile children <5 years of age and adults who were positive for P. falciparum by RDT were treated according to national and Integrated Management of Childhood Illness guidelines with artemether/lumefantrine, which has a lingering 4-week prophylactic effect on parasitemia. However, inclusion of artemether/lumefantrine–treated participants did
not affect the relevant proportions of malaria infection at month 1 (online Technical Appendix Table 5).

AZT treatment occurred at the village level, which might have exacerbated similarities in malaria risk among participants in the same village and created village-level clustering (25). Clustering within villages can bias results if it is not addressed in the statistical models (30). Village-level random effects were used to adjust variance estimates for within-village clustering and provide valid multilevel statistical inferences, given the clustering inherent in the study design (20,31). We argue that a relevant comparison is between the proportion of AZT MDA–treated and control villages, rather than a grouping of 4 villages in each AZT MDA intervention and control villages. Grouping findings into only 8 units on a village level does not produce relevant results and was not the design of the study.

AZT MDA was conducted occurred according to the WHO SAFE (surgery, antibiotics, facial cleanliness, and environmental changes) trachoma control strategy, and as- signing treatment to villages by randomization would have been unethical because of the established effectiveness of this strategy in the study region. AZT MDA was examined from an observational perspective with the longitudinal cohort. We sought to minimize lack of comparability by selecting villages from a similar geographic region and by controlling for bednet ownership and altitude in multivari- ate analysis. We believe that residual confounding and bias are minimal because similar P. falciparum infection prevalence rates were observed at baseline and at months 3–6 after the effect of the AZT MDA had decreased.

In Ethiopia, Porco et al. reported a 49% (95% CI 10%–71%) decrease in odds of death in a randomized trial of AZ MDA villages compared with control villages that received a single dose of AZ (20 mg/kg to ≤1 g) (10). AZT protection from P. falciparum infection might have contributed to the overall decrease in deaths. Although the effect of AZT MDA on prevalent infections was strong, most infections observed were asymptomatic. The study in Ethiopia also had 3 dosing strategies (annual, biannual, and quarterly), which resulted in two thirds of study participants receiving more annual doses than used in the

### Table 3. Multivariate association between AZ MDA and Plasmodium falciparum prevalence with village-level random effects, Tanzania, January 12–July 21, 2009*

| Time       | AZT MDA treatment, yes/no | Bednets, yes/no | Altitude, m |
|------------|---------------------------|-----------------|-------------|
| Baseline   | 1.16 (0.725–1.849)         | 0.75 (0.483–1.158) | 0.99 (0.984–0.996) |
| Month 1    | 0.37 (0.188–0.743)†        | 0.78 (0.418–1.439) | 1.01 (1.002–1.017) |
| Month 3    | 0.70 (0.922–1.64)          | 1.55 (0.862–3.65)  | 1.00 (0.992–1.012) |
| Month 4    | 0.62 (0.078–4.919)         | 0.40 (0.095–1.673) | 1.02 (0.997–1.044) |
| Month 6    | 0.50 (0.074–3.347)         | 1.54 (0.235–10.094) | 0.99 (0.966–1.016) |

*Values are odds ratio (95% CI). AZT, azithromycin; MDA, mass drug administration. †p<0.005.

### Table 4. Resistance markers for cloned sequences of Plasmodium falciparum ribosomal PRr14 protein gene, Tanzania, January 12–July 21, 2009*

| Patient ID | Time from azithromycin treatment, d | Parasites/μL by light microscopy | Parasites/μL by real-time PCR | RDT result | No. plasmid clones with WT sequence | Clones with synonymous SNP (no.) | Clones with nonsynonymous SNP (no.) | No. plasmids sequenced |
|------------|-----------------------------------|---------------------------------|-------------------------------|------------|----------------------------------|----------------------------------|-----------------------------------|-----------------------|
| 1          | 30                                | 31,200                          | 5,378                         | +          | 7                                | L112L (1)                        | 0                                 | 8                     |
| 2          | 30                                | ND                              | 3,177                         | ND         | 3                                | 0                                | 0                                 | 3                     |
| 3          | 30                                | ND                              | 224.9                         | ND         | 0                                | K36K (4)                         | 0                                 | 4                     |
| 4          | 67                                | 151,000                         | 126,506                       | +          | 2                                | 0                                | 0                                 | 2                     |
| 5          | 69                                | 74,400                          | 55,850                        | –          | 1                                | S85S (1)                         | 0                                 | 2                     |
| 6          | 80                                | 49,160                          | 16,410                        | +          | 4                                | 0                                | I38V (1), N109S (1), N166D (1)  | 7                     |
| 7          | 82                                | 1,840                           | 679                           | +          | 1                                | 0                                | F114L (1)                        | 2                     |
| 8          | 94                                | 26,760                          | 11,030                        | –          | 1                                | 0                                | T56I (1)                         | 2                     |
| 9          | 127                               | 0                               | 51,075                        | +          | 3                                | 0                                | 0                                 | 3                     |
| 10         | 132                               | ND                              | 22,774                        | ND         | 0                                | 0                                | I39S (1), S65N (1)               | 4                     |
| 11         | NT                                | 0                               | 69,718                        | +          | 13                               | 0                                | A78S (1), I126T (1), K100R and I126T (1), N166S (1), Y20H, K100%, and I139T (1) | 18                    |
| 12         | NT                                | 11,160                          | 2,495                         | +          | 2                                | 0                                | 0                                 | 2                     |
| Control    | NT                                | ND                              | 2,495                         | +          | 2                                | 0                                | 0                                 | 2                     |
| Control    | NT                                | ND                              | 2,495                         | +          | 2                                | 0                                | 0                                 | 2                     |

*ID, identification; RDT, rapid diagnostic test; WT, wild type; SNP, single-nucleotide polymorphism; +, positive; ND, not done; –, negative; NT, not treated. †An A78S nonsynonymous SNP in region associated with azithromycin resistance that was not present in other clones.
study in Tanzania. Our data provide only weak evidence that a reduction in malaria infection contributed to the reduction in deaths reported in Ethiopia.

At the study site, we did not find evidence of *P. falciparum* AZT resistance markers on a gene previously implicated in AZT resistance in vitro. We also observed a short-lived but major reduction in malaria. AZT MDA does not produce *Plasmodium* spp. drug resistance probably because other drugs with different mechanisms of action are used to treat malaria. This study might provide an optimistic note for AZ MDA planners and those living in areas in developing nations to which malaria and trachoma are endemic.

Acknowledgments

We thank Harran Mkocha, Diane Stare, and the PretPlus study team for providing tireless efforts during this study; Edward Sambu and Fikirini Msuya for assisting with training of local field staff and reading peripheral blood smears; Stephen Magasa for providing technical support; and Natalie Sanders for assisting with DNA sequencing.

This study was supported by the Bill and Melinda Gates Foundation (grant 48027); Research to Prevent Blindness (unrestricted grant); and the National Institute of Allergy and Infectious Diseases (grant U01 AI068613: (HIV Prevention Trials Network—Laboratory Network). Pfizer, Inc. donated the azithromycin for the study. S.W. was supported by a Senior Scientific Award from Research to Prevent Blindness.

Dr Schachterle is an associate director at Pfizer, Inc., New York, NY. His primary research interest is spatial analysis of infectious diseases.

References

1. Sidhu AB, Sun Q, Nkrumah LJ, Dunne MW, Sacchettini JC, Fidock DA. In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. J Biol Chem. 2007;282:2494–504. http://dx.doi.org/10.1074/jbc.M608615200
2. Duran JM, Amsden GW. Azithromycin: indications for the future? Expert Opin Pharmacother. 2000;1:489–505. http://dx.doi.org/10.1517/14656566.1.3.489
3. Friesen J, Silvie O, Putrianti ED, Hafalla JC, Matuschewski K, Borrmann S. Natural immunization against malaria: causal prophylaxis with antibiotics. Sci Transl Med. 2010;2:240ra49. http://dx.doi.org/10.1126/scitranslmed.3001058
4. Shimizu S, Osada Y, Kanazawa T, Tanaka Y, Arai M. Suppressive effect of azithromycin on *Plasmodium berghei* mosquito stage development and apicoplast replication. Malar J. 2010;9:73. http://dx.doi.org/10.1186/1475-2875-9-73
5. Burton MJ, Mabey DC. The global burden of trachoma: a review. PLoS Negl Trop Dis. 2009;3:e460. http://dx.doi.org/10.1371/journal.pntd.0000460
6. Mathew AA, Turner A, Taylor HR. Strategies to control trachoma. Drugs. 2009;69:953–70. http://dx.doi.org/10.2165/00003495-20090608-00002
7. West SK, Munoz B, Mckocha H, Gaydos CA, Quinn TC. Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania. J Infect Dis. 2011;204:268–73. http://dx.doi.org/10.1093/infdis/jir257
8. Polack S, Brooker S, Kuper H, Mariotti S, Mabey D, Foster A. Mapping the global distribution of trachoma. Bull World Health Organ. 2005;83:913–9.
9. Sadiq ST, Glasgow KW, Drakeley CJ, Muller O, Greenwood BM, Mabey DC, et al. Effects of azithromycin on malariometric indices in The Gambia. Lancet. 1995;346:881–2. http://dx.doi.org/10.1016/S0140-6736(95)92712-3
10. Porco TC, Gebre T, Ayele B, House J, Keenan J, Zhou Z, et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA. 2009;302:962–8. http://dx.doi.org/10.1001/jama.2009.1266
11. Keenan JD, Ayele B, Gebre T, Zerihun M, Zhou Z, House JI, et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin Infect Dis. 2011;52:883–8. http://dx.doi.org/10.1093/cid/cir069
12. Sykes A, Hendriksen I, Mtove G, Mandeav V, Mrrema H, Rutta B, et al. Azithromycin plus artesunate versus artemether-lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial. Clin Infect Dis. 2009;49:1195–201. http://dx.doi.org/10.1086/595063
13. van Eijk AM, Terlouw DJ. Azithromycin for treating uncomplicated malaria. Cochrane Database Syst Rev. 2011:2.CD006688.
14. Andersen SL, Olof AJ, Gordon DM, Ragama OB, Aleman GM, Berman JD, et al. Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis. 1998;26:146–50. http://dx.doi.org/10.1086/516281
15. Heppner DG Jr, Walsh DS, Uthaimongkol N, Tang DB, Tulyayon S, Permpanch B, et al. Randomized, controlled, double-blind trial of daily oral azithromycin in adults for the prophylaxis of *Plasmodium vivax* malaria in western Thailand. Am J Trop Med Hyg. 2005;73:842–9.
16. Taylor WR, Richie TL, Fryauff DJ, Picarima H, Ohrt C, Tang D, et al. Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled field trial in Irian Jaya, Indonesia. Clin Infect Dis. 1999;28:74–81. http://dx.doi.org/10.1086/515071
17. Taylor WR, Richie TL, Fryauff DJ, Ohrt C, Picarima H, Tang D, et al. Tolerability of azithromycin as malaria prophylaxis in adults in northeast Papua, Indonesia. Antimicrob Agents Chemother. 2003;47:2199–203. http://dx.doi.org/10.1128/AAC.47.7.2199-2203.2003
18. Coles CL, Levens J, Seidman JC, Mckocha H, Munoz B, West S. Mass distribution of azithromycin for trachoma control is associated with short-term reduction in risk of acute lower respiratory infection in young children. Pediatr Infect Dis J. 2012;31:341–6. http://dx.doi.org/10.1097/INF.0b013e31824155c9
19. Coles CL, Seidman JC, Levens J, Mckocha H, Munoz B, West S. Association of mass treatment with azithromycin in trachoma-endemic communities with short-term reduced risk of diarrhea in young children. Am J Trop Med Hyg. 2011;85:691–6. http://dx.doi.org/10.4269/ajtmh.2011.11-0046
20. Schachterle SE, Mtove G, Levens JP, Clemens EG, Shi L, Raj A, et al. Prevalence and density-related concordance of three diagnostic tests for malaria in a region of Tanzania with hypoendemic malaria. J Clin Microbiol. 2011;49:3885–91. http://dx.doi.org/10.1128/JCM.01157-11
21. Taylor R, Todd M, Kongloa L, Maurice L, Nahozya E, Sanga H, et al. Evidence of the dependence of groundwater resources on extreme rainfall in east Africa. Nature Climate Change. 2013;3:374–8. http://dx.doi.org/10.1038/nclimate1731
22. World AgroMeteorological Information Service, Southern African Development Community (SADC). SADC Agromet Bulletin Jan 21–31, 2009 [cited 2014 Feb 24]. http://wamis.gmu.edu/countries/sadc_rev.php
23. National Bureau of Statistics. Tanzania HIV/AIDS and malaria indicator survey: key findings. Calverton (MD): The Bureau; 2009.

24. Reller ME, Clemens EG, Schachterle SE, Mtove GA, Sullivan DJ, Dumler JS. Multiplex 5\textsuperscript{′} nuclease-quantitative PCR for diagnosis of relapsing fever in a large Tanzanian cohort. J Clin Microbiol. 2011;49:3245–9. http://dx.doi.org/10.1128/JCM.00940-11

25. Waller L, Gotway C. Applied spatial statistics for public health data. Hoboken (NJ): Wiley-IEEE; 2004.

26. Diggle P, Ribeiro P Jr, Christensen O. An introduction to model-based geostatistics. Spatial Statistics and Computational Methods. 2003;173:43–86. http://dx.doi.org/10.1007/978-0-387-21811-3_2

27. R Development Core Team. R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing; 2008.

28. Rowlingson B, Diggle P. SPLANCNS: spatial and space-time point pattern analysis. R package version 2.01–27; 2010 [cited 2014 Feb 24]. https://r-forge.r-project.org/svn/viewvc.php/pkg/splanck/DESCRIPTION?pathrev=1194&sortby=date&root=rspatial&sortdir=down&view=diff&rl=1111&rt=1112

29. Bates D, Maechler M, Dai D. lme4:Linear mixed-effects models using S4 classes. R package version 0.999375–42; 2008 [cited 2014 Feb 24]. http://lme4.r-forge.r-project.org/

30. von Seidelein L, Greenwood BM. Mass administrations of anti-malarial drugs. Trends Parasitol. 2003;19:452–60. http://dx.doi.org/10.1016/j.pt.2003.08.003

31. Diggle P, Heagerty P, Liang K, Zeger S. Analysis of longitudinal data. 2nd ed. New York: Oxford University Press; 2002.

Address for correspondence: David J. Sullivan, Department of Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe St, Rm E5628, Baltimore, MD 21205, USA; email: dsullivan@jhsph.edu
Short-Term Malaria Reduction by Single-Dose Azithromycin during Mass Drug Administration for Trachoma, Tanzania

Technical Appendix

Alternative analysis of baseline and month 1 comparisons for short-term malaria reduction by single-dose azithromycin during mass drug administration for trachoma, Tanzania, January 12–July 21, 2009

Technical Appendix Table 1. Village-level comparisons of baseline with month 1 for AZT MDA, Tanzania, January 12–July 21, 2009*

| Village | AZT MDA | Time     | No. patients negative | No. patients positive | p value |
|---------|---------|----------|-----------------------|-----------------------|---------|
| 1       | Yes     | Baseline | 225                   | 7                     |         |
|         | Yes     | Month 1  | 183                   | 6                     | 1       |
| 3       | Yes     | Baseline | 230                   | 5                     |         |
|         | Yes     | Month 1  | 193                   | 0                     | 0.0489  |
| 4       | Yes     | Baseline | 203                   | 23                    |         |
|         | Yes     | Month 1  | 162                   | 2                     | 0.0002  |
| 6       | Yes     | Baseline | 143                   | 18                    |         |
|         | Yes     | Month 1  | 111                   | 1                     | 0.0005  |
| 2       | No      | Baseline | 234                   | 0                     |         |
|         | No      | Month 1  | 186                   | 6                     | 0.008   |
| 5       | No      | Baseline | 190                   | 40                    |         |
|         | No      | Month 1  | 155                   | 4                     | 0.0001  |
| 7       | No      | Baseline | 199                   | 11                    |         |
|         | No      | Month 1  | 148                   | 7                     | 0.81    |
| 8       | No      | Baseline | 217                   | 3                     |         |
|         | No      | Month 1  | 155                   | 19                    | 0.001   |

*AZT, azithromycin; MDA, mass drug administration.

Technical Appendix Table 2. Effect of AZT MDA by age, Tanzania, January 12–July 21, 2009*

| Time       | Treatment | No. patients negative | No. patients positive |
|------------|-----------|-----------------------|-----------------------|
| Prevalence in persons 1–10 y of age |            |                       |                       |
| Baseline   | No AZT    | 357                   | 26                    |
|            | AZT       | 346                   | 22                    |
| Month 1    | No AZT    | 319                   | 14                    |
|            | AZT       | 355                   | 5†                   |
| Prevalence in persons >10 y of age |            |                       |                       |
| Baseline   | No AZT    | 403                   | 23                    |
|            | AZT       | 383                   | 27                    |
| Month 1    | No AZT    | 356                   | 21                    |
|            | AZT       | 415                   | 9†                   |

*AZT, azithromycin; MDA, mass drug administration.
†Significantly different (p = 0.0338) from control in univariate model.
‡Significantly different (p = 0.0142) from control in univariate and multivariate models when controlling for altitude, rainfall, and village-level random effect.
### Technical Appendix Table 3. Effect of AZT treatment on an individual level for untreated persons who lived in a village that received AZT and who then moved to a village that did not receive AZT, Tanzania, January 12–July 21, 2009*

| Time    | Individual treatment | 18S ribosomal gene of *Plasmodium falciparum* | OR (95% CI) for patients given AL | OR (95% CI) for patients not given AL |
|---------|----------------------|---------------------------------------------|----------------------------------|--------------------------------------|
|         |                      | No. patients | No. patients | No. patients |                                |                                   |
| Baseline| No AZT               | 909          | 58           | 0            | 1.05 (0.69–1.58)                | 1.05 (0.69–1.58)                  |
|         | AZT                  | 732          | 49           | 0            |                               |                                   |
| Month 1 | No AZT               | 811          | 38           | 54           | 0.36 (0.18–0.67)†              | 0.36 (0.18–0.70)†                 |
|         | AZT                  | 768          | 13           | 36           |                               |                                   |
| Month 3 | No AZT               | 704          | 20           | 89           | 0.81 (0.41–1.61)               | 0.65 (0.29–1.41)                  |
|         | AZT                  | 649          | 12           | 73           |                               |                                   |
| Month 4 | No AZT               | 571          | 10           | 110          | 0.37 (0.09–1.25)              | 0.29 (0.05–1.15)                  |
|         | AZT                  | 584          | 3            | 92           |                               |                                   |
| Month 6 | No AZT               | 640          | 4            | 139          | 1.11 (0.25–4.83)              | 1.12 (0.21–6.06)                  |
|         | AZT                  | 570          | 4            | 134          |                               |                                   |

*AL, artemether/lumefantrine; OR, odds ratio; AZT, azithromycin.
†p = 0.0015.

### Technical Appendix Table 4. Effect of AZT treatment for patients who did not receive AZT (herd effect), Tanzania, January 12–July 21, 2009*

| Time    | Village treatment | 18S ribosomal gene of *Plasmodium falciparum* | OR (95% CI) for patients given AL | OR (95% CI) for patients not given AL |
|---------|-------------------|---------------------------------------------|----------------------------------|--------------------------------------|
|         |                   | No. patients | No. patients | No. patients |                                |                                   |
| Baseline| No AZT            | 840          | 54           | 0            | 0.90 (0.23–2.556)               | 0.90 (0.23–2.556)                  |
|         | AZT               | 69           | 4            | 0            |                               |                                   |
| Month 1 | No AZT            | 742          | 37           | 52           | 0.27 (0.01–1.653)              | 0.29 (0.01–1.78)                  |
|         | AZT               | 69           | 1            | 2            |                               |                                   |
| Month 3 | No AZT            | 653          | 17           | 86           | 2.04 (0.38–7.21)               | 2.26 (0.41–8.18)                  |
|         | AZT               | 51           | 3            | 3            |                               |                                   |
| Month 4 | No AZT            | 523          | 8            | 106          | 2.68 (0.28–13.42)              | 2.72 (0.27–14.15)                 |
|         | AZT               | 48           | 2            | 4            |                               |                                   |
| Month 6 | No AZT            | 589          | 4            | 133          | 0 (0–14.11)                   | 0 (0–17.87)                      |
|         | AZT               | 51           | 0            | 6            |                               |                                   |

*AL, artemether/lumefantrine; OR, odds ratio; AZT, azithromycin.

### Technical Appendix Table 5. Comparison of persons given azithromycin with untreated persons, by village level, Tanzania, January 12–July 21, 2009*

| Time    | Village treatment | 18S ribosomal gene of *Plasmodium falciparum* | OR (95% CI) for patients given AL | OR (95% CI) for patients not given AL |
|---------|-------------------|---------------------------------------------|----------------------------------|--------------------------------------|
|         |                   | No. patients | No. patients | No. patients |                                |                                   |
| Baseline| No AZT            | 840          | 54           | 0            | 1.03 (0.68–1.55)               | 1.03 (0.68–1.55)                  |
|         | AZT               | 801          | 53           | 0            |                               |                                   |
| Month 1 | No AZT            | 742          | 37           | 52           | 0.33 (0.17–0.62)†              | 0.34 (0.17–0.64)†                 |
|         | AZT               | 837          | 14           | 38           |                               |                                   |
| Month 3 | No AZT            | 653          | 17           | 86           | 0.96 (0.48–1.89)              | 0.82 (0.38–1.77)                  |
|         | AZT               | 700          | 15           | 76           |                               |                                   |
| Month 4 | No AZT            | 523          | 8            | 106          | 0.58 (0.17–1.82)              | 0.52 (0.13–1.81)                  |
|         | AZT               | 632          | 5            | 96           |                               |                                   |
| Month 6 | No AZT            | 589          | 4            | 133          | 0.95 (0.22–4.14)              | 0.95 (0.18–5.12)                  |
|         | AZT               | 621          | 4            | 140          |                               |                                   |

*AL, artemether/lumefantrine; OR, odds ratio; AZT, azithromycin.
†p = 0.0003.